VWF/ADAMTS13 Imbalance, But Not Global Coagulation or Fibrinolysis, Is Associated With Outcome and Bleeding in Acute Liver Failure.
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
03
07
2020
received:
09
06
2020
accepted:
26
07
2020
pubmed:
9
8
2020
medline:
6
1
2022
entrez:
9
8
2020
Statut:
ppublish
Résumé
Recent studies of acute liver failure (ALF) in man and animals have suggested that rebalanced hemostasis occurs, with distinct hypercoagulable features clinically evidenced by a low risk of bleeding. Rodent models have shown a link between intrahepatic microthrombus formation and progression of ALF. We sought to confirm these earlier findings in a large series of patients with well-characterized ALF from the Acute Liver Failure Study Group. Citrated plasma samples taken on admission from 676 patients with ALF or acute liver injury (international normalized ratio ≥2.0 without hepatic encephalopathy) were used to determine levels of von Willebrand factor (VWF), a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity, thrombomodulin-modified thrombin generation, and clot lysis time (CLT) and compared with the levels in 40 healthy controls. Patients had 3-fold increased VWF levels, 4-fold decreased ADAMTS13 activity, similar thrombin generating capacity, and 2.4-fold increased CLT, compared with controls. Increasing disease severity was associated with progressively more elevated VWF levels as well as hypofibrinolysis. Patients who died or underwent liver transplantation within 21 days of admission had higher VWF levels, lower ADAMTS13 activity, but similar thrombin generation and a similar proportion of patients with severe hypofibrinolysis, when compared with transplant-free survivors. Likewise, patients with bleeding complications had higher VWF levels and lower ADAMTS13 activity compared to those without bleeding. Thrombin generation and CLT did not differ significantly between bleeding and nonbleeding patients. Rebalanced hemostatic status was confirmed in a large cohort of patients with acute liver injury/ALF, demonstrating that VWF/ADAMTS13 imbalance is associated with poor outcome and bleeding. The association between VWF/ADAMTS13 imbalance and bleeding suggests that bleeding in ALF relates more to systemic inflammation than a primary coagulopathy.
Sections du résumé
BACKGROUND AND AIMS
Recent studies of acute liver failure (ALF) in man and animals have suggested that rebalanced hemostasis occurs, with distinct hypercoagulable features clinically evidenced by a low risk of bleeding. Rodent models have shown a link between intrahepatic microthrombus formation and progression of ALF. We sought to confirm these earlier findings in a large series of patients with well-characterized ALF from the Acute Liver Failure Study Group.
APPROACH AND RESULTS
Citrated plasma samples taken on admission from 676 patients with ALF or acute liver injury (international normalized ratio ≥2.0 without hepatic encephalopathy) were used to determine levels of von Willebrand factor (VWF), a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity, thrombomodulin-modified thrombin generation, and clot lysis time (CLT) and compared with the levels in 40 healthy controls. Patients had 3-fold increased VWF levels, 4-fold decreased ADAMTS13 activity, similar thrombin generating capacity, and 2.4-fold increased CLT, compared with controls. Increasing disease severity was associated with progressively more elevated VWF levels as well as hypofibrinolysis. Patients who died or underwent liver transplantation within 21 days of admission had higher VWF levels, lower ADAMTS13 activity, but similar thrombin generation and a similar proportion of patients with severe hypofibrinolysis, when compared with transplant-free survivors. Likewise, patients with bleeding complications had higher VWF levels and lower ADAMTS13 activity compared to those without bleeding. Thrombin generation and CLT did not differ significantly between bleeding and nonbleeding patients.
CONCLUSIONS
Rebalanced hemostatic status was confirmed in a large cohort of patients with acute liver injury/ALF, demonstrating that VWF/ADAMTS13 imbalance is associated with poor outcome and bleeding. The association between VWF/ADAMTS13 imbalance and bleeding suggests that bleeding in ALF relates more to systemic inflammation than a primary coagulopathy.
Identifiants
pubmed: 32767567
doi: 10.1002/hep.31507
pmc: PMC8251778
doi:
Substances chimiques
von Willebrand Factor
0
ADAMTS13 Protein
EC 3.4.24.87
ADAMTS13 protein, human
EC 3.4.24.87
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1882-1891Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK058369
Pays : United States
Informations de copyright
© 2020 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
Références
Blood. 2010 Aug 12;116(6):878-85
pubmed: 20400681
J Thromb Haemost. 2015 Sep;13(9):1642-52
pubmed: 26178257
Liver Int. 2018 Nov;38(11):1988-1996
pubmed: 29768734
J Hepatol. 2012 Jan;56(1):129-36
pubmed: 21703173
Arch Pharm Res. 2012 Oct;35(10):1693-9
pubmed: 23139119
Clin Gastroenterol Hepatol. 2016 Apr;14(4):613-620.e4
pubmed: 26453953
Br J Haematol. 2005 Apr;129(1):93-100
pubmed: 15801961
J Thromb Haemost. 2012 Jul;10(7):1312-9
pubmed: 22568491
Blood. 2005 Feb 1;105(3):1102-5
pubmed: 15466929
Am J Gastroenterol. 2017 Sep;112(9):1389-1396
pubmed: 28440304
Br J Surg. 2016 May;103(6):735-743
pubmed: 27005894
BMC Anesthesiol. 2019 Jun 11;19(1):97
pubmed: 31185916
Aliment Pharmacol Ther. 2012 Jun;35(11):1245-56
pubmed: 22506515
Liver Int. 2014 May;34(5):672-8
pubmed: 24164805
Blood. 2008 Feb 1;111(3):1295-8
pubmed: 17928530
Gastroenterology. 2008 Jul;135(1):41-60
pubmed: 18549814
J Crit Care. 2018 Feb;43:54-60
pubmed: 28843665
J Hepatol. 2012 Oct;57(4):780-6
pubmed: 22735303
Blood. 2010 Jul 8;116(1):113-21
pubmed: 20385790
Semin Thromb Hemost. 2017 Mar;43(2):178-184
pubmed: 27472427
J Clin Invest. 2011 Feb;121(2):522-4
pubmed: 21266772
Hepatology. 2007 Oct;46(4):1177-86
pubmed: 17654741
J Hepatol. 2020 Jan;72(1):146-155
pubmed: 31606553
Hepatology. 2018 May;67(5):1931-1942
pubmed: 29194678
Blood. 2017 Nov 9;130(19):2055-2063
pubmed: 28912376
Blood. 2001 Sep 15;98(6):1662-6
pubmed: 11535495
Eur J Gastroenterol Hepatol. 2019 Aug;31(8):1040-1048
pubmed: 30768435
Thromb Haemost. 2019 Feb;119(2):246-253
pubmed: 30609442
Gut. 2011 Aug;60(8):1133-8
pubmed: 21427197
Hepatology. 2020 Oct;72(4):1327-1340
pubmed: 32614088
Hepatol Int. 2018 May;12(3):204-213
pubmed: 29858744
J Clin Gastroenterol. 1986 Dec;8(6):664-8
pubmed: 3805667
Hepatology. 2011 Apr;53(4):1323-32
pubmed: 21480334
Q J Med. 1975 Oct;44(176):615-26
pubmed: 172938
Semin Thromb Hemost. 2015 Jul;41(5):468-73
pubmed: 26049071
J Thromb Haemost. 2018 Jan;16(1):6-18
pubmed: 29108103
Blood. 2017 May 25;129(21):2836-2846
pubmed: 28416507
Hepatology. 2020 Aug;72(2):584-594
pubmed: 31773739
Hepatology. 2013 Aug;58(2):752-61
pubmed: 23468040
Aliment Pharmacol Ther. 2018 Apr;47(7):980-988
pubmed: 29377193
Blood. 2013 Mar 7;121(10):1868-74
pubmed: 23305736
Scand J Gastroenterol Suppl. 1973;19:63-70
pubmed: 4515642